Sanofi-Blueprint Medicines deal received US antitrust clearance
MLex Summary: The US waiting period for Sanofi's acquisition of Blueprint Medicines for $9.5 billion has expired, Blueprint said in a filing with the US Securities and Exchange Commission.Extract....To view the full article, register now.
Already a subscriber? Click here to view full article